CNSY

Market-moving news on Cerenome (NASDAQ: CNSY): filings, earnings, deals and other events, from REDFILED.

Cerenome's CNSide platform analyzes cerebrospinal fluid to detect cancer cells in the central nervous system.

CNSY

CERENOME Secures Up to $20 Million Royalty-Based Credit Facility

The CNS oncology company got initial funding at closing from 3i Fund and says its cash runway now extends well into 2028.

Cerenome has agreed to a multi-tranche senior secured convertible note financing.

CNSY

CERENOME Issues Senior Secured Convertible Notes at $2.74 Conversion Price

The company sold senior secured convertible notes with a 6% original issue discount, 8% annual interest and multiple closings under a September 4 purchase agreement.